Fig. 3From: Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III studyPercentage change from extension baseline in tumor volume 12 months after crossover. Percentage change in tumor volume after a switching to pasireotide LAR and b switching to octreotide LARBack to article page